Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 8;9(10):1147.
doi: 10.3390/vaccines9101147.

Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases

Giuseppe A Ramirez  1   2 , Chiara Asperti  1   2 , Valentina Cucca  1   2 , Mona-Rita Yacoub  1   2
Affiliations
Review

Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases

Giuseppe A Ramirez et al. Vaccines (Basel). .

Abstract

Aberrant deployment of the immune response is a hallmark pathogenic feature of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease (COVID-19), possibly accounting for high morbidity and mortality, especially in patients with comorbidities, including immune-mediated disorders. Immunisation with SARS-COV-2 vaccines successfully instructs the immune system to limit viral spread into tissues, mitigate COVID-19 manifestations and prevent its most detrimental inflammatory complications in the general population. Patients with immune-mediated diseases have been excluded from vaccine registration trials, foreclosing the acquisition of specific efficacy and safety data. In this review, we aimed to summarise and critically discuss evidence from real-world studies addressing this issue to provide a comprehensive view of the impact of vaccination practices in patients with allergy, autoimmunity or immunodeficiency. We analysed clinical and laboratory data from 34 studies involving more than 13,000 subjects with various immune disorders who were vaccinated with mRNA- DNA- or inactivated viral particle-based vaccines. These data globally support the safe and effective use of SARS-CoV-2 vaccines in patients with immune-mediated diseases, although patient-tailored strategies to determine vaccination timing, vaccine choice and background therapy management are warranted to optimise vaccination outcomes. More data are needed regarding patients with primary immunodeficiencies.

Keywords: COVID-19; allergy; autoimmune diseases; mastocytosis; primary immunodeficiency; rheumatic diseases; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they do not have any conflict of interest in connection with this paper.

References

    1. Jowett B., editor. Thucydides. History of the Peloponnesian War. Early Fourth Century BC. Clarendon Press; Oxford, UK: 1881. Book II. Chapter 47–54.
    1. Morgan A.J., Parker S. Translational mini-review series on vaccines: The Edward Jenner Museum and the history of vaccination. Clin. Exp. Immunol. 2007;147:389–394. doi: 10.1111/j.1365-2249.2006.03304.x. - DOI - PMC - PubMed
    1. Pardi N., Hogan M.J., Porter F.W., Weissman D. mRNA vaccines—A new era in vaccinology. Nat. Rev. Drug Discov. 2018;17:261–279. doi: 10.1038/nrd.2017.243. - DOI - PMC - PubMed
    1. Miyachi T., Takita M., Senoo Y., Yamamoto K. Lower trust in national government links to no history of vaccination. Lancet. 2020;395:31–32. doi: 10.1016/S0140-6736(19)32686-8. - DOI - PubMed
    1. Hammam N., Tharwat S., Shereef R.R.E., Elsaman A.M., Khalil N.M., Fathi H.M., Salem M.N., El-Saadany H.M., Samy N., El-Bahnasawy A.S., et al. Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: The vaXurvey study from Egypt. Rheumatol. Int. 2021;41:1607–1616. doi: 10.1007/s00296-021-04941-0. - DOI - PMC - PubMed

LinkOut - more resources